Press releases

Glycorex Transplantation AB (GTAB): Interim Report January-March 2021

Wed, May 19 2021, 6:00 GMT+0200 | Interim report | Regulatory release

January - March 2021 (compared to the  corresponding period last year)

  • Net sales: SEK 4.9 million (7.7). 
  • Operating income: SEK -5.3 million (0.2).•
  • Net income for the period: SEK -5.3 million (0.3).
  • Earnings per share: SEK -0.07 (0.00), no dilution effects. 
  • Covid-19 continued to affect sales, but with large variation between countries.
  • Europe continues to be the most important region with good growth in Spain, the Czech Republic and France.  
  • Positive trend in our largest market Germany in the latter part of the quarter, but overall COVID-19 impacted negatively with a 36 percent decrease in sales.
  • Sales recovery in India indicates improved transplant activities, but the market is difficult to assess due to the current COVID-19 situation.
  • Continued severe pandemic condition in Mexico with a major impact on sales.
  • Strong end to the quarter and positive signals from the market inspire optimism.
  • Glycosorb® ABO received approval from the Ministryof Health in Turkey – the world’s 3rd largest market for kidney transplants from living donors.
  • New website and graphic profile launched – focus on strengthened communication.
First quarter Full year
SEK Thousands Jan-Mar 2021 Jan-Mar 2020 Jan-Dec 2020 Jan-Dec 2019
Net sales 4 923 7 674 27 000 36 105
Change in stocks of finished goods -159 -252 -81 1 098
Own work capitalized 191 602 1 640 3 477
Other operating income 103 272 1 654 604
Total 5 058 8 296 30 213 41 284
Operating expenses
Raw materials and supplies -427 -966 -3 929 -4 479
Other external expenses -2 367 -1 965 -9 284 -7 925
Personnel expenses -5 373 -3 787 -16 419 -15 803
Depreciation and amortization of  fixed assets -2 114 -1 258 -7 830 -5 089
Other operating expenses -64 -143 -475 -488
Operating income -5 287 177 -7 724 7 500
Net financial items -85 156 -326 -624
Income before tax -5 372 333 -8 050 6 876
Taxes 26 - 10 30
Net income -5 346 333 -8 040 6 906
Earnings per share, SEK -0,07 0,00 -0,11 0,10


CEO comments

Positive sales development after weak start of the year

The COVID-19 pandemic continued to affect our sales during the first quarter of the year. The recovery in transplant operations varies greatly between countries, which is also reflected in our sales. After a very weak January, the trend has been positive with increasing demand in several markets. During the quarter, we continued our marketing efforts in the blood bank and transfusion segment with our new universal blood plasma (UBP) product. Furthermore, we have worked intensively to build a completely new communication platform with the launch of a new website and graphic profile, clearly reflecting our continued growth ambitions.

 

Covid-19 continued to affect sales in the first quarter

Sales during the quarter amounted to SEK 4.9 million (7.7) after continued negative impact from the pandemic. We see signs of recovery in the field of transplantation, but with large regional and national differences. In Europe, sales recovered in February and March with good performance in Spain and the Czech Republic, among others. France also accounts for stable growth. Germany had a weak performance for the quarter as a whole but showed strong pickup in February and March. As previously reported, sales in India and Mexico have been heavily affected by COVID-19. It was therefore particularly gratifying that India had a sales increase of 62 percent in the quarter. However, given the recent rapid spread of COVID-19 in India, it is difficult to assess transplant development in the country in the near future. Mexico continues to have a difficult pandemic situation and the same applies to Turkey, which negatively affects our sales in these countries.

Overall, sales decreased by 36 percent during the quarter as a result of the pandemic. After the end of the quarter, we have received continued positive signals from the market, which gives optimism for the future. Our current assessment is that the number of transplants will return to normal levels once the vaccination programs take effect. After that, we will have the opportunity to complete our planned market expansion. Exactly when this will happen is, of course, difficult to predict. 

Market development in the field of transplantation

Europe continues to be the driving force of our sales, accounting for more than 80 percent of sales in the first quarter. We continue our efforts to create the conditions for growth in the major markets in India, Mexico, and Turkey, which are estimated to have an annual potential of up to SEK 185 million for Glycosorb® ABO. As previously communicated, Glycosorb® ABO has received approval in Turkey and our distributor has initiated sales activities. For broad market penetration, it is important to be part of the reimbursement system and initiatives for this process have been started by our partner in Turkey.

The United States is the country where the most of kidney transplants is carried out in the world, with a market potential for Glycosorb® ABO estimated at SEK 160 million. The preparatory work required to start an FDA registration in the United States, has resumed in 2021, having previously been paused due to COVID-19.

Commercialization of UBP

Our strategy to pre-launch the UBP product through our own sales channels is ongoing. The ambition is to allow well-selected reference customers in Europe and the United States to evaluate UBP and publish the results, thereby creating a platform for a broader launch of the UBP product. The level of activity towards key customers has been high during the quarter resulting in several ongoing evaluations of UBP. To build our network within this for us new segment, we have engaged in the International Society of Blood Transfusion (ISBT), as a corporate partner. I would also like to mention the ongoing evaluation of UBP for whole blood in the United States, which is progressing according to plan.

Development of a new product for the treatment of rheumatoid arthritis (RA)

Our work to develop a treatment for RA (rheumatoid arthritis) continued during the quarter. Up to 10 percent of patients do not respond to today’s treatments and here we see great potential for Glycorex to improve medical treatment. Our ambition is to start clinical studies within the RA project in 2021 given that the COVID-19 situation allows this. Given the great potential and medical benefits, the RA project is a high priority in our development work.

New communication platform and IR activities 

Communication with our customers, partners and shareholders is important to us and here the website is a central part. During the first quarter, we have therefore developed a new website. With the new website, we are starting with increased communication in general and digital communication in particular. In addition, we have launched a new graphic profile to reflect our ambitions. We have also expanded our social media presence and it is now possible to follow us on LinkedIn, Twitter, and Facebook. Our new communication platform breathes forward thinking and confidence, which is fully in line with the opportunities I see for Glycorex. Furthermore, We will increase our IR activities and next up are presentations at the Biostock Life Science Spring Summit and RedEye Growth Day in May and June respectively.

Priorities in 2021

To conclude, we will continue to work to strengthen our positions in the transplant field both in the important European market and in our emerging markets India, Mexico, and Turkey. Another prioritized area in this segment is the registration work in the United States. The commercialization work for UBP will continue unabated with the ambition that UBP will be included in several scientific publications during the year. On the development side, we prioritize the RA project, and our goal is to start clinical studies in 2021 that, in the event of a positive outcome, will form the basis for an upcoming CE marking.

It is with confidence that I look forward to the coming quarters and our efforts to create value for patients, healthcare, society and ultimately our shareholders!

Pontus Nobréus,
CEO Glycorex Transplantation AB

  

THE COMPLETE INTERIM REPORT FOR Q1 IS ATTACHED

This is a translation of the Swedish version of the Interim report.  When in doubt, the Swedish wording prevails.
 


This disclosure contains information that Glycorex Transplantation is obliged to make public pursuant to the EU Market Abuse Regulation and the Swedish Securities Markets Act. The information was submitted for publication, through the agency of the contact person, on May 19, 2019 08:00 CET.

News in swedish

Glycorex Transplantation AB (GTAB): Interim Report January-March 2021

Wed, May 19 2021, 6:00 GMT+0200 | Interim report | Regulatory release

January - March 2021 (compared to the  corresponding period last year)

  • Net sales: SEK 4.9 million (7.7). 
  • Operating income: SEK -5.3 million (0.2).•
  • Net income for the period: SEK -5.3 million (0.3).
  • Earnings per share: SEK -0.07 (0.00), no dilution effects. 
  • Covid-19 continued to affect sales, but with large variation between countries.
  • Europe continues to be the most important region with good growth in Spain, the Czech Republic and France.  
  • Positive trend in our largest market Germany in the latter part of the quarter, but overall COVID-19 impacted negatively with a 36 percent decrease in sales.
  • Sales recovery in India indicates improved transplant activities, but the market is difficult to assess due to the current COVID-19 situation.
  • Continued severe pandemic condition in Mexico with a major impact on sales.
  • Strong end to the quarter and positive signals from the market inspire optimism.
  • Glycosorb® ABO received approval from the Ministryof Health in Turkey – the world’s 3rd largest market for kidney transplants from living donors.
  • New website and graphic profile launched – focus on strengthened communication.
First quarter Full year
SEK Thousands Jan-Mar 2021 Jan-Mar 2020 Jan-Dec 2020 Jan-Dec 2019
Net sales 4 923 7 674 27 000 36 105
Change in stocks of finished goods -159 -252 -81 1 098
Own work capitalized 191 602 1 640 3 477
Other operating income 103 272 1 654 604
Total 5 058 8 296 30 213 41 284
Operating expenses
Raw materials and supplies -427 -966 -3 929 -4 479
Other external expenses -2 367 -1 965 -9 284 -7 925
Personnel expenses -5 373 -3 787 -16 419 -15 803
Depreciation and amortization of  fixed assets -2 114 -1 258 -7 830 -5 089
Other operating expenses -64 -143 -475 -488
Operating income -5 287 177 -7 724 7 500
Net financial items -85 156 -326 -624
Income before tax -5 372 333 -8 050 6 876
Taxes 26 - 10 30
Net income -5 346 333 -8 040 6 906
Earnings per share, SEK -0,07 0,00 -0,11 0,10


CEO comments

Positive sales development after weak start of the year

The COVID-19 pandemic continued to affect our sales during the first quarter of the year. The recovery in transplant operations varies greatly between countries, which is also reflected in our sales. After a very weak January, the trend has been positive with increasing demand in several markets. During the quarter, we continued our marketing efforts in the blood bank and transfusion segment with our new universal blood plasma (UBP) product. Furthermore, we have worked intensively to build a completely new communication platform with the launch of a new website and graphic profile, clearly reflecting our continued growth ambitions.

 

Covid-19 continued to affect sales in the first quarter

Sales during the quarter amounted to SEK 4.9 million (7.7) after continued negative impact from the pandemic. We see signs of recovery in the field of transplantation, but with large regional and national differences. In Europe, sales recovered in February and March with good performance in Spain and the Czech Republic, among others. France also accounts for stable growth. Germany had a weak performance for the quarter as a whole but showed strong pickup in February and March. As previously reported, sales in India and Mexico have been heavily affected by COVID-19. It was therefore particularly gratifying that India had a sales increase of 62 percent in the quarter. However, given the recent rapid spread of COVID-19 in India, it is difficult to assess transplant development in the country in the near future. Mexico continues to have a difficult pandemic situation and the same applies to Turkey, which negatively affects our sales in these countries.

Overall, sales decreased by 36 percent during the quarter as a result of the pandemic. After the end of the quarter, we have received continued positive signals from the market, which gives optimism for the future. Our current assessment is that the number of transplants will return to normal levels once the vaccination programs take effect. After that, we will have the opportunity to complete our planned market expansion. Exactly when this will happen is, of course, difficult to predict. 

Market development in the field of transplantation

Europe continues to be the driving force of our sales, accounting for more than 80 percent of sales in the first quarter. We continue our efforts to create the conditions for growth in the major markets in India, Mexico, and Turkey, which are estimated to have an annual potential of up to SEK 185 million for Glycosorb® ABO. As previously communicated, Glycosorb® ABO has received approval in Turkey and our distributor has initiated sales activities. For broad market penetration, it is important to be part of the reimbursement system and initiatives for this process have been started by our partner in Turkey.

The United States is the country where the most of kidney transplants is carried out in the world, with a market potential for Glycosorb® ABO estimated at SEK 160 million. The preparatory work required to start an FDA registration in the United States, has resumed in 2021, having previously been paused due to COVID-19.

Commercialization of UBP

Our strategy to pre-launch the UBP product through our own sales channels is ongoing. The ambition is to allow well-selected reference customers in Europe and the United States to evaluate UBP and publish the results, thereby creating a platform for a broader launch of the UBP product. The level of activity towards key customers has been high during the quarter resulting in several ongoing evaluations of UBP. To build our network within this for us new segment, we have engaged in the International Society of Blood Transfusion (ISBT), as a corporate partner. I would also like to mention the ongoing evaluation of UBP for whole blood in the United States, which is progressing according to plan.

Development of a new product for the treatment of rheumatoid arthritis (RA)

Our work to develop a treatment for RA (rheumatoid arthritis) continued during the quarter. Up to 10 percent of patients do not respond to today’s treatments and here we see great potential for Glycorex to improve medical treatment. Our ambition is to start clinical studies within the RA project in 2021 given that the COVID-19 situation allows this. Given the great potential and medical benefits, the RA project is a high priority in our development work.

New communication platform and IR activities 

Communication with our customers, partners and shareholders is important to us and here the website is a central part. During the first quarter, we have therefore developed a new website. With the new website, we are starting with increased communication in general and digital communication in particular. In addition, we have launched a new graphic profile to reflect our ambitions. We have also expanded our social media presence and it is now possible to follow us on LinkedIn, Twitter, and Facebook. Our new communication platform breathes forward thinking and confidence, which is fully in line with the opportunities I see for Glycorex. Furthermore, We will increase our IR activities and next up are presentations at the Biostock Life Science Spring Summit and RedEye Growth Day in May and June respectively.

Priorities in 2021

To conclude, we will continue to work to strengthen our positions in the transplant field both in the important European market and in our emerging markets India, Mexico, and Turkey. Another prioritized area in this segment is the registration work in the United States. The commercialization work for UBP will continue unabated with the ambition that UBP will be included in several scientific publications during the year. On the development side, we prioritize the RA project, and our goal is to start clinical studies in 2021 that, in the event of a positive outcome, will form the basis for an upcoming CE marking.

It is with confidence that I look forward to the coming quarters and our efforts to create value for patients, healthcare, society and ultimately our shareholders!

Pontus Nobréus,
CEO Glycorex Transplantation AB

  

THE COMPLETE INTERIM REPORT FOR Q1 IS ATTACHED

This is a translation of the Swedish version of the Interim report.  When in doubt, the Swedish wording prevails.
 


This disclosure contains information that Glycorex Transplantation is obliged to make public pursuant to the EU Market Abuse Regulation and the Swedish Securities Markets Act. The information was submitted for publication, through the agency of the contact person, on May 19, 2019 08:00 CET.

Subscribe to our releases

Choose categories

Contact information

The subscription service is provided by Cision.se and your information will be stored on their servers. The information will only be used to send you notifications when new releases are published. No personal information will be shared with any outside parties. Read more about our Privacy Policy.

News

Pontus Nobréus, CEO presenting Glycorex Transplantation on Redeye Growth Day june 2.
Presentationen >>

Download the presentationen >>

 

 

Pontus Nobréus, CEO presenting Glycorex Transplantation  BioStock Life Science Spring Summit on May 26
https://youtu.be/5fpTsNENiO8

Download the presentation >>

Glycorex Transplantation is a proud collaborator with The Hospital Clínic de Barcelona in Spain. It recently became the first hospital in Spain to carry out more than 1,000 living donor kidney transplants. To celebrate this milestone, a campaign called “A thousand transplants, a thousand stories” was launched to increase public awareness and encourage living donor kidney donations. https://www.clinicbarcelona.org/en/news/the-hospital-clinic-the-first-hospital-in-spain-to-carry-out-1-000-living-donor-kidney-transplants

REDEYE GROWTH DAY
Pontus Nobréus, CEO of Glycorex Transplantation will present at the Redeye Growth Day on June 2, 2021 at 08:50 CET.
Link to live streaming: https://www.redeye.se/events/808637/redeye-growth-day-2021

Glycorex Transplantation participates in the BioStock Life Science Spring Summit 2021. CEO Pontus Nobréus will present the company at the BioStock Life Science Spring Summit on May 26-27. For more information please visit: www.summit.biostock.se

Tomorrow, april 29th, Dr Guirado from Spain will discuss ABO incompatible kidney transplantations in a live Zoom seminar, arranged by our distributor in Mexcio, Ryse Médica and Sociedad Mexicana De Transplantes.

https://us02web.zoom.us/j/85789158554

Scheelevägen 27 | SE-223 63 Lund, Sweden

Phone: +46 46 286 52 30  | Fax: +46 46-286 52 39
E-mail: info@glycorex.com

Org.nr: 556519-7372

© 2021 Glycorex Transplantation AB. Registered office in Lund, Sweden . All rights reserved.